



OPEN

# Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Joseph E. Ebinger<sup>1</sup>, Justyna Fert-Bober<sup>1,2</sup>, Ignat Printsev<sup>3</sup>, Min Wu<sup>1</sup>, Nancy Sun<sup>1</sup>, John C. Prostko<sup>4</sup>, Edwin C. Frias<sup>4</sup>, James L. Stewart<sup>4</sup>, Jennifer E. Van Eyk<sup>1,2</sup>, Jonathan G. Braun<sup>1,2</sup>, Susan Cheng<sup>1,6</sup> and Kimia Sobhani<sup>1,6</sup>

**In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients ( $n=1,090$ ), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection ( $n=35$ ) were similar to those seen after two doses of vaccine in individuals without prior infection ( $n=228$ ). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.**

Messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), offer great promise for curbing the spread of infection<sup>1–3</sup>. Challenges to the supply chain have prompted queries around whether single-dose administration rather than double-dose administration might suffice for certain individuals, including those recovered from prior infection. Emerging immune data, including detectable presence of anti-SARS-CoV-2 antibodies and virus-specific T cells, have suggested possible alternate vaccination strategies for previously infected individuals<sup>4–6</sup>. Recent small studies have indicated that individuals with prior infection might have naturally acquired immunity that could be sufficiently enhanced by a single dose rather than a double dose of administered vaccine<sup>7,8</sup>. To this end, we evaluated SARS-CoV-2-specific antibody responses after the first and second doses of the BNT162b2 (Pfizer–BioNTech) mRNA vaccine in a large and diverse cohort of healthcare workers. We compared the responses of individuals with confirmed prior infection to those of individuals without prior evidence of infection.

We enrolled healthcare workers from across a large academic medical center in Southern California. Vaccine recipients ( $n=1,090$ ) who provided at least one blood sample for antibody testing were aged  $41.9 \pm 12.2$  years and were 60.7% female and 53.3% non-White (Table 1): 981 vaccine recipients, including 78 with prior SARS-CoV-2 infection, provided baseline (pre-vaccine) samples; 525 (35 with prior infection) provided samples after dose 1; and 239 (11 with prior infection) provided samples after dose 2. A total of 217 individuals (ten with prior infection) provided blood samples at all three time points. Antibody levels were measured at

three time points: before or up to 3 d after dose 1; within 7–21 d after dose 1; and within 7–21 d after dose 2. Because the timing of the first blood draw for antibody testing could confound the association of spike glycoprotein-specific IgG (IgG(S-receptor-binding domain (RBD))) with prior infection versus early vaccine response<sup>9</sup>, we used nucleoprotein-specific IgG (IgG(N)) to denote prior SARS-CoV-2 exposure while recognizing a small potential for representing cross-reactivity with other coronaviruses. Given that the BNT162b2 vaccine delivers mRNA encoding only for spike protein, the expected elicited response is production of IgG(S-RBD) antibodies and not IgG(N) antibodies<sup>10</sup>; furthermore, IgG(N) antibodies are also known to represent a durable marker and indicator of post-infectious status<sup>11</sup>. Accordingly, we determined prior SARS-CoV-2 infection status and timing in relation to the first vaccine date, based on concordance of data documented in health records, presence of any IgG(N) antibodies at baseline pre-vaccination testing and the self-reported survey information collected. All cases of data discrepancy regarding prior SARS-CoV-2 infection status underwent manual physician adjudication, including medical chart review for evidence of positive SARS-CoV-2 polymerase chain reaction (PCR) or antibody testing that could have been performed by outside institutions or otherwise documented in the medical record.

For both IgG(N) (representing response to prior infection) and IgG(S-RBD) (representing response to either prior infection or vaccine), as expected, individuals with prior SARS-CoV-2 infection had higher antibody levels at all time points ( $P \leq 0.001$ ) (Supplementary Tables 1 and 2 and Extended Data Fig. 1). Notably, IgG(S-RBD) levels were only slightly lower in previously infected individuals at baseline when compared to infection-naïve individuals who had received a single vaccine dose (log-median AU ml<sup>-1</sup> (interquartile range, 6.0 (4.6, 6.9) versus 7.0 (6.3, 7.6)),  $P < 0.001$ ). Moreover, IgG(S-RBD) levels were not significantly different among previously infected individuals after a single dose and infection-naïve individuals who had received two doses (10.0 (9.2, 10.4) versus 9.9 (9.4, 10.3),  $P = 0.92$ ) (Fig. 1). Similar results were found in a sensitivity analysis including only individuals who had antibody immunoassays performed at all three time points (Supplementary Tables 3 and 4). Specifically, those with prior infection had higher IgG(S-RBD) than

<sup>1</sup>Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. <sup>2</sup>Advanced Clinical Biosystems Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. <sup>3</sup>F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. <sup>4</sup>Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA. <sup>5</sup>Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. <sup>6</sup>These authors contributed equally: Jonathan G. Braun, Susan Cheng, Kimia Sobhani. ✉e-mail: [jonathan.braun2@cshs.org](mailto:jonathan.braun2@cshs.org); [susan.cheng@cshs.org](mailto:susan.cheng@cshs.org); [kimia.sobhani@cshs.org](mailto:kimia.sobhani@cshs.org)

**Table 1 | Characteristics of the study cohort**

	Total	Pre-vaccine	Post-vaccine dose 1	Post-vaccine dose 2
<i>n</i>	1,090	981	525	239
Age in years, mean (s.d.)	41.89 (12.18)	41.60 (12.05)	43.66 (12.79)	44.12 (12.65)
Race, <i>n</i> (%)				
White	509 (46.7)	453 (46.2)	263 (50.1)	130 (54.4)
Black or African American	36 (3.3)	33 (3.4)	22 (4.2)	9 (3.8)
Asian	300 (27.5)	265 (27.0)	154 (29.3)	67 (28.0)
Native Hawaiian/Pacific Islander	29 (2.7)	27 (2.8)	14 (2.7)	3 (1.3)
American Indian/Alaska Native	2 (0.2)	2 (0.2)	0 (0.0)	0 (0.0)
Multiple/other	139 (12.8)	130 (13.2)	58 (11.1)	27 (11.4)
Prefer not to answer	75 (6.9)	71 (7.2)	14 (2.6)	3 (1.3)
Ethnicity, <i>n</i> (%)				
Hispanic/Latinx	139 (12.8)	126 (12.8)	55 (10.5)	20 (8.4)
Non-Hispanic/Latinx	881 (80.8)	788 (80.3)	460 (87.6)	216 (90.4)
Prefer not to answer	70 (6.4)	67 (6.8)	10 (1.9)	3 (1.3)
Sex, <i>n</i> (%)				
Male	362 (33.2)	331 (33.7)	159 (30.3)	65 (27.2)
Female	662 (60.7)	587 (59.8)	353 (67.2)	168 (70.3)
Other	1 (0.1)	1 (0.1)	1 (0.2)	1 (0.4)
Prefer not to answer	65 (6.0)	62 (6.3)	12 (2.3)	5 (2.1)
Prior SARS-CoV-2 infection, <i>n</i> (%)	86 (7.9)	78 (8.0)	35 (6.7)	11 (4.6)
Antibody levels, mean (%)				
Architect IgG index (S/C) (IgG(N))	0.30 (0.86)	0.25 (0.84)	0.36 (0.90)	0.34 (0.82)
Architect IgM index (S/C)	0.99 (2.41)	0.26 (1.24)	2.11 (4.11)	3.38 (5.96)
Architect Quant IgG II (AU ml <sup>-1</sup> ) (IgG(S-RBD))	2,801.04 (6,159.27)	103.90 (693.89)	3,183.38 (7,299.73)	24,084.06 (16,367.63)


those without prior infection at all time points. No difference in IgG(S-RBD) levels was detected between those with prior infection after one dose of vaccine and those without prior infection after two doses (10.2 (8.4, 10.5) versus 9.9 (9.4, 10.3),  $P=0.58$ ).

For surrogate measures of antibody neutralization, we examined IgG(S-RBD) levels at or above 4,160 AU ml<sup>-1</sup> given that this threshold corresponds to a 0.95 probability of obtaining a plaque reduction neutralization test (PRNT) ID<sub>50</sub> at a 1:250 dilution. Proportions of IgG(S-RBD)  $\geq$  4,160 AU ml<sup>-1</sup> were similar between previously infected individuals at baseline compared to infection-naïve individuals after a single dose ( $P=1.00$ ). Notably, these proportions were lower in previously infected individuals after a single dose than in infection-naïve individuals after two doses ( $P<0.001$ ); there were no between-group differences after two doses (Supplementary Table 5 and Extended Data Fig. 2). We also used an angiotensin-converting enzyme 2 (ACE2) binding inhibition assay that correlates well with the SARS-CoV-2 PRNT methodology and exhibits a high correlation with the IgG(S-RBD) assay threshold ( $r^2=0.95$ ). We found that ACE2 binding inhibition was significantly higher among previously infected individuals than infection-naïve individuals after a single vaccine dose (94.3% versus 37.3%,  $P<0.001$ ), with no between-group difference seen after the second dose (100.0% versus 97.8%,  $P=1.00$ ). In time-shifted analyses, there was no difference in ACE2 binding between individuals with prior SARS-CoV-2 infection after a single dose and infection-naïve individuals after two doses (94.3% versus 97.8%,  $P=0.52$ ) (Supplementary Table 6 and Extended Data Fig. 3).

In parallel with antibody response analyses, we also examined post-vaccine symptomatology (Supplementary Tables 7–11

and Extended Data Fig. 4). We observed that previously infected individuals experienced significant post-vaccine symptoms (that is, reactogenicity) more frequently than infection-naïve individuals after dose 1 (36.8% versus 25.0%,  $P=0.03$ ). However, there was no between-group difference in significant symptoms after dose 2 (51.3% versus 58.7%,  $P=0.26$ ). In time-shifted analyses, infection-naïve individuals had higher reactogenicity after dose 2 than previously infected individuals after their first dose (58.7% versus 36.8%,  $P<0.001$ ). Fever and chills were more common among previously infected vaccine recipients after the first dose, whereas infection-naïve individuals were more likely to experience headache, dizziness or lightheadedness after the second dose. In analyses of changes from dose 1 to dose 2, reactogenicity increased in frequency for infection-naïve individuals (25.0% versus 58.7%,  $P<0.001$ ) and less so in previously infected individuals (36.8% versus 51.3%,  $P=0.08$ ).

Overall, we found that individuals previously infected with SARS-CoV-2 developed vaccine-induced antibody responses after a single dose of the BNT162b2 (Pfizer–BioNTech) mRNA vaccine that were similar to antibody responses seen after a two-dose vaccination course administered to infection-naïve individuals. Our findings in a large and diverse cohort of healthcare workers expand from the results of smaller studies that have indicated higher levels of anti-S antibodies at baseline, and after a single mRNA vaccine dose, in previously infected individuals compared to those without prior infection<sup>7,8,12,13</sup>. In a total cohort of over 1,000 vaccine recipients, including several hundred with blood sampling after administered vaccine doses, we found that the anti-S antibody response after a single vaccine dose in previously infected individuals was



**Fig. 1 | IgG(S-RBD) antibody response to mRNA SARS-CoV-2 vaccination in individuals with and without prior SARS-CoV-2 infection.** Box plots display the median values with the interquartile range (lower and upper hinge) and  $\pm 1.5$ -fold the interquartile range from the first and third quartile (lower and upper whiskers). We used two-sided Wilcoxon tests, without adjustment for multiple testing, to perform the following between-group comparisons: (1) infection-naïve individuals ( $n=903$ ) and those with prior infection ( $n=78$ ), both at baseline ( $P < 0.001$ ); (2) infection-naïve individuals ( $n=490$ ) and those with prior infection ( $n=35$ ), both after dose 1 ( $P < 0.001$ ); (3) infection-naïve individuals ( $n=228$ ) and those with prior infection ( $n=11$ ), both after dose 2 ( $P < 0.001$ ); (4) infection-naïve individuals ( $n=490$ ) after dose 1 and those with prior infection ( $n=78$ ), both at baseline ( $P < 0.001$ ); and (5) infection-naïve individuals ( $n=228$ ) after dose 2 and those with prior infection ( $n=35$ ) after dose 1 ( $P=0.92$ ).

similar to the response seen after two doses in all vaccine recipients irrespective of prior infection status. We further assessed the neutralization potential of elicited antibodies using a high-throughput ACE2 inhibition neutralization surrogate assay. Similarly to findings from a smaller study that directly measured antibody neutralizing capacity in 59 volunteers<sup>8</sup>, we found, in our large cohort, that a second vaccine dose did not offer previously infected individuals a substantially greater benefit over a single dose in antibody neutralizing potential. Thus, our data suggest that a single dose of the Pfizer–BioNTech vaccine is sufficient for individuals with prior SARS-CoV-2 infection, not only when considering the response in anti-S antibody levels but also when examining results of an ACE2 inhibition assay indicating the potential neutralizing capability of elicited antibodies.

Limitations of our study include the 21-d timeframe within which antibodies were measured after each vaccine dose. Longer-term follow-up can provide additional information regarding the putative duration of immunity acquired from receiving a single dose versus a double dose of vaccine. Measures of T cell responses can shed further light on how a single dose versus a double dose of vaccine might be sufficient for augmenting T cell memory in previously infected individuals<sup>12</sup>. Further studies are needed to determine if a certain window for vaccination timing might be optimal to maximize efficacy as well as safety in previously infected individuals. Larger-sized cohorts are needed for sufficient statistical power to examine differences across demographic and clinical subgroups that are known to exhibit variation in antibody responses after vaccination<sup>14–16</sup>. When neutralizing capacity was estimated using a conservative IgG(S-RBD) threshold of  $>4,160$  AU ml<sup>-1</sup>, the single-dose response in previously infected individuals was numerically similar, albeit statistically significantly lower, than the antibody response after two doses in infection-naïve individuals. When applying this conservative threshold of  $>4,160$  AU ml<sup>-1</sup>, which correlates with

a 95% probability of high neutralizing antibody titer<sup>17</sup>, statistical comparisons are susceptible to the influence of extreme values in the context of smaller-sized subgroups. Notably, there was no significant difference in the surrogate measure of ACE2 binding inhibition between persons with and without prior infection in time-shifted analysis after vaccine dose 1 and dose 2, respectively. Notwithstanding methodological differences between examining IgG(S-RBD) levels and assays of ACE2 binding inhibition, these surrogate measures suggest materially similar levels of achieved neutralization capacity. Some variation in antibody responses might also be related to heterogeneity within previously infected individuals, including in timing and severity of prior illness. Although circulating antibody levels alone are not definitive measures of immune status, serial measures of the serological response to either natural or inoculated exposures are known to correlate well with effective protective immunity<sup>18</sup>, and our results indicate their potential utility in guiding vaccine deployment strategies for both previously infected and infection-naïve individuals.

Our results offer preliminary evidence in support of a middle ground between public health-motivated and immunologically supported vaccine strategies. If validated, an approach that involves providing a single dose of vaccine to individuals with a confirmed history of SARS-CoV-2 infection along with an on-time complete vaccine schedule for infection-naïve individuals could maximize the benefit of a limited vaccine supply.

### Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-021-01325-6>.

Received: 23 February 2021; Accepted: 18 March 2021;  
Published online: 1 April 2021

### References

- Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N. Engl. J. Med.* **384**, 403–416 (2020).
- Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N. Engl. J. Med.* **383**, 2603–2615 (2020).
- Omer, S. B., Yildirim, I. & Forman, H. P. Herd immunity and implications for SARS-CoV-2 control. *JAMA* **324**, 2095–2096 (2020).
- Melgaco, J. G., Azamor, T. & Ano Bom, A. P. D. Protective immunity after COVID-19 has been questioned: what can we do without SARS-CoV-2-IgG detection? *Cell Immunol.* **353**, 104114 (2020).
- Harvey, R.A. et al. Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection. Preprint at <https://www.medrxiv.org/content/10.1101/2020.12.18.20248336v1> (2020).
- Lumley, S. F. et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. *N. Engl. J. Med.* **384**, 533–540 (2020).
- Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMc2101667> (2021).
- Saadat, S. et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. *JAMA* <https://doi.org/10.1001/jama.2021.3341> (2021).
- Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Sci. Transl. Med.* **13**, eabd2233 (2021).
- Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature* **586**, 594–599 (2020).
- Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat. Microbiol.* **5**, 1598–1607 (2020).
- Prendecki, M. et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. *Lancet* [https://doi.org/10.1016/S0140-6736\(21\)00502-X](https://doi.org/10.1016/S0140-6736(21)00502-X) (2021).
- Manisty, C. et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. *Lancet* **397**, 1057–1058 (2021).

14. Soiza, R.L., Scicluna, C. & Thomson, E.C. Efficacy and safety of COVID-19 vaccines in older people. *Age Ageing* **50**, 279–283 (2020).
15. Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature* **588**, 315–320 (2020).
16. Abu Jabal, K. et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. *Euro. Surveill.* **26**, 2100096 (2021).
17. *SARS-CoV-2 IgG II Quant Assay User Manual* (Abbott Laboratories, Diagnostics Division, 2020).
18. Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature* <https://www.nature.com/articles/s41586-021-03324-6> (2021).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021



## Methods

We collected plasma samples from a cohort of healthcare workers who received Pfizer–BioNTech vaccination at our medical center in Southern California<sup>19</sup>. Serological testing for antibodies to the RBD of the S1 subunit of the viral spike protein (IgG (S-RBD)) and antibodies targeting the viral nucleocapsid protein (IgG(N)) was performed at Abbott Labs using the SARS-CoV-2 IgG II assay and SARS-CoV-2 IgG assay, respectively. Antibody levels were measured at three time points: before or up to 3 d after dose 1; within 7–21 d after dose 1; and within 7–21 d after dose 2. We considered an IgG(N) S/C of  $\geq 1.4$  as denoting seropositive status due to prior SARS-CoV-2 exposure based on a previously established cutoff<sup>20</sup>.

For assessing potential response of neutralizing antibodies, we considered a conservatively high IgG(S-RBD) threshold of 4,160 AU ml<sup>-1</sup> as a correlate of neutralization. The 4,160 AU ml<sup>-1</sup> threshold has been shown to corresponded to a 0.95 probability of obtaining a PRNT ID<sub>50</sub> at a 1:250 dilution as a representative high titer; thus, we examined the proportion of vaccine recipients who achieved this IgG(S-RBD) threshold<sup>17</sup> after administration of each dose of vaccine. Furthermore, as a high-throughput method of directly assessing viral inhibition (or neutralization), we also employed a research ACE2 binding inhibition assay to measure the ability of detected IgG(S-RBD) antibodies to inhibit viral spike protein from binding to ACE2 receptors. This ACE2 binding inhibition assay, which we applied to the post-vaccination samples, is known to correlate well with SARS-CoV-2 PRNT methodology and exhibits a high correlation with the IgG(S-RBD) assay threshold employed ( $r^2 = 0.95$ ).

All participants provided survey data on prior SARS-CoV-2 infection and symptoms experienced after each vaccine dose. We used an online REDCap<sup>21,22</sup> questionnaire to survey all participants regarding post-vaccination symptoms, including presence or absence of distinct symptom types as well as the severity and duration of any symptom experienced. We administered the questionnaire 8 d after each vaccine dose. We defined a post-vaccine symptom reaction as significant if reported as a non-injection site symptom that was: (1) moderate to severe in degree and lasting <2 d or (2) of any severity and lasting >2 d. We determined prior SARS-CoV-2 infection status and timing in relation to first vaccine date, based on concordance of data documented in health records, presence of IgG(N) antibodies at baseline pre-vaccination testing and the self-reported survey information collected. All cases of data discrepancy regarding prior SARS-CoV-2 infection status underwent manual physician adjudication, including medical chart review for evidence of positive SARS-CoV-2 PCR or antibody testing that was performed by outside institutions.

**Statistical analyses.** We compared antibody levels and symptom responses between individuals with and without a prior SARS-CoV-2 infection diagnosis. We analyzed data at both matched and shifted time points, including measures for individuals with a prior infection (at baseline and after dose 1) compared to infection-naïve individuals (after dose 1 and dose 2). We log-transformed non-normally distributed values. For comparing between-group continuous values, we used the non-parametric Wilcoxon rank sum test. For comparing between-group proportions (for example, values above a given threshold), we used two-sided chi-square tests with the Yates correction. We performed sensitivity analyses for those individuals with immunoassays at all three time points. We conducted all statistical analyses using R (v3.6.1) and considered statistical significance as a two-tailed  $P$  value <0.05. All participants provided written informed consent, and all protocols were approved by the Cedars-Sinai institutional review board.

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

Requests for de-identified data may be directed to the corresponding authors (J.G.B., S.C. and K.S.) and will be reviewed by the Office of Research Administration at Cedars-Sinai Medical Center before issuance of data sharing agreements. Data limitations are designed to ensure patient and participant confidentiality.

## References

19. Ebinger, J. E. et al. Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study. *BMJ Open* **11**, e043584 (2021).

20. Chew, K. L. et al. Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection. *Clin. Microbiol. Infect.* **26**, 1256.e9–1256.e11 (2020).
21. Harris, P. A. et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J. Biomed. Inf.* **42**, 377–381 (2009).
22. Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. *J. Biomed. Inf.* **95**, 103208 (2019).

## Acknowledgements

We are grateful to all the frontline healthcare workers in our healthcare system who continue to be dedicated to delivering the highest quality care for all patients. We thank the following people for their collective effort: F. P. Aguirre; K. Ahmad; C. M. Albert; M. Alotaibi; A. Andres; M. Arditi; A. Balmanoukian; C. Becker; J. Beekley; D. Benliyan; A. H. Berg; E. Biener-Ramanujan; A. Binek; P. Botting; G. J. Botwin; D. Casero; C. Chavira; B. Chazarin Orgel; M. Che; P. Chen; V. Chiu; D. Choi; M. Chow; C. Chung; C. Climer; B. Coleman; S. Contreras; R. Coren; D. Costales; W. Cozen; T. Dar; J. Davis; T. Davis; P. Debbas; J. Diaz; J. Dos Santos; M. Driver; K. R. Dunn; R. Ely; M. Faries; B. Fields; J. C. Figueiredo; L. Florindez; J. Foley; N. Fontelera; S. Francis; J. A. Golden; A. Gonzalez; H. S. Goodridge; J. Gonzalez; J. D. Grein; G. Guidry; O. Hamid; M. Hanna; S. Hashemzadeh; M. Heath; E. Herrera; A. Hoang; L. Huang; K. Huballa; Q. Hurlburt; S. K. Hussain; C. A. Huynh; J. Ibrahim; U. Ihenacho; M. Jain; H. Jawanda; M. Jordan; A. Jose-Isip; S. Joung; M. Karin; E. H. Kim; L. Kim; M. M. Kittleson; E. Kowalewski; C. N. Le; N. A. Leonard; Y. Li; Y. Liu; J. Lloyd; E. Luong; A. Makaryan; B. Malladi; D.-M. Manalo; D. Marshall; A. McArdle; D. P. B. McGovern; I. Mehmi; D. Mejia; G. Y. Melmed; L. Mendez; E. Mengesha; A. Merchant; N. Merin; K. S. Michelsen; G. Milan; P. B. Miles; J. Miller; M. Minissian; R. Miranda-Peats; S. E. Mirzadeh; A. Moore; P. Moore; J. Moreno; A. Mujukian; N. Nguyen; T. T. Nguyen; M. Noval Rivas; F. N. Bitghe; M. Offner; J. Oft; E. Park; E. Park; V. Patel; C. Phebus; L. Piro; L. R. Polak; A. Porter; M. Puccio; K. Raedschelders; V. K. Ramanujan; R. Ramirez; G. Ramirez; M. Rashid; K. Reckamp; K. Rhoades; C. E. Riera; R. V. Riggs; A. Rivas; J. Robertson; M. Salas; M. Schafieh; R. Shane; S. Sharma; C. Simons; M. Soomar; S. Sternbach; N. Sun; C. Svendsen; B. Tep; R. O. Tompkins; W. G. Toutelotte; R. Vallejo; C. Velasco; M. Velasquez; K. Washington; K. Wentzel; S. White; B. Wong; M. Wong; M. Yatawara; R. Zabner; C. Zamudio; Y. Zhang; L. Zhou; P. Zvara. Funding: This work was supported, in part, by Cedars-Sinai Medical Center (J.E.E., M.W., N.S. and S.C.); the Erika J. Glazer Family Foundation (J.E.E., M.W., N.S., J.E.V.E. and S.C.); the F. Widjaja Family Foundation (I.P. and J.G.B.); the Helmsley Charitable Trust (I.P. and J.G.B.); and National Institutes of Health grants U54-CA260591 (J.E.E., J.F.B., M.W., J.E.V.E., J.G.B., S.C. and K.S.) and K23-HL153888 (J.E.E.).

## Author contributions

J.E.E., J.G.B., S.C. and K.S. conceived and designed the study and participated in data collection, analysis, writing of the manuscript and revision of the manuscript. J.F.B. and I.P. participated in data collection and analysis. M.W., N.S., J.C.P., E.C.F. and J.L.S. participated in analysis. J.E.V.E. participated in data collection, analysis and writing of the manuscript.

## Competing interests

J.C.P., E.C.F. and J.L.S. work for Abbott Diagnostics, a company that performed the serological assays on the biospecimens that were collected for this study. The remaining authors have no competing financial interests.

## Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41591-021-01325-6>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41591-021-01325-6>.


**Correspondence and requests for materials** should be addressed to J.G.B., S.C. or K.S.

**Peer review information** *Nature Medicine* thanks the anonymous reviewers for their contribution to the peer review of this work. Editor recognition statement: Saheli Sadanand was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.


**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).



**Extended Data Fig. 1 | Anti-Nucleocapsid Protein IgG Antibody Response to mRNA SARS-CoV-2 Vaccination in Persons With and Without Prior SARS-CoV-2 infection.** Box plots display the median values with the interquartile range (lower and upper hinge) and  $\pm 1.5$ -fold the interquartile range from the first and third quartile (lower and upper whiskers). We used two-sided Wilcoxon tests, without adjustment for multiple testing, to conduct the following between-group comparisons: (1) infection naïve ( $n = 903$ ) and those with prior infection ( $n = 78$ ), both at baseline ( $P < 0.001$ ); (2) infection naïve ( $n = 490$ ) and those with prior infection ( $n = 35$ ), both following dose 1 ( $P < 0.001$ ); (3) infection naïve ( $n = 228$ ) and those with prior infection ( $n = 11$ ), both following dose 2 ( $P < 0.001$ ); (4) infection naïve ( $n = 490$ ) following dose 1 and those with prior infection ( $n = 78$ ) at baseline ( $P < 0.001$ ); and, (5) infection naïve ( $n = 228$ ) following dose 2 and those with prior infection ( $n = 35$ ) following dose 1 ( $P < 0.001$ ).




**Extended Data Fig. 2 | Anti-Spike Receptor Binding Domain IgG Antibody Response to mRNA SARS-CoV-2 Vaccination in Persons With and Without Prior SARS-CoV-2 Infection: Values Above and Below 4160 AU/mL.** Box plots display the median values with the interquartile range (lower and upper hinge) and  $\pm 1.5$ -fold the interquartile range from the first and third quartile (lower and upper whiskers). We used two-sided Chi-Square tests with the Yate's correction, without adjustment for multiple testing, to conduct the following between-group comparisons: (1) infection naïve ( $n = 221$ ) following dose 2 and those with prior infection ( $n = 27$ ) following dose 1 ( $P < 0.001$ ); and, (2) infection naïve ( $n = 221$ ) and those with prior infection ( $n = 11$ ), both following dose 2 ( $P = 1.00$ ).



**Extended Data Fig. 3 | ACE2 Antibody Binding Capacity in Persons With and Without Prior SARS-CoV-2 infection: Values Above and Below 50%.**

Box plots display the median values with the interquartile range (lower and upper hinge) and  $\pm 1.5$ -fold the interquartile range from the first and third quartile (lower and upper whiskers). Colors denote values above and below the 50% neutralizing threshold. We used two-sided Wilcoxon tests, without adjustment for multiple testing, to conduct the following between-group comparisons: (1) infection naïve ( $n = 490$ ) and those with prior infection ( $n = 35$ ), both following dose 1 ( $P < 0.001$ ); (2) infection naïve ( $n = 228$ ) and those with prior infection ( $n = 11$ ), both following dose 2 ( $P = 1.00$ ); and, (3) infection naïve ( $n = 228$ ) following dose 2 and those with prior infection ( $n = 35$ ) following dose 1 ( $P = 0.52$ ).





**Extended Data Fig. 4 | Post-Vaccination Symptoms in Persons With and Without Prior SARS-CoV-2 infection.** Bar graphs display the frequency and severity of symptoms reported following each dose of vaccine administered, by prior infection status.

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection No custom algorithms or software used.

Data analysis All statistical analyses were conducted using R v3.6.1 and no custom code packages were used. All code used for analyses is available upon request.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Requests for deidentified data may be sent to the corresponding author and are reviewed by Cedars-Sinai Medical Center prior to issuance of data sharing agreements. The data are not publicly available due to the contents containing information that could compromise participant privacy.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	We studied data collected from a total of N=1090 vaccine recipients who provided at least one blood sample for antibody testing and represented the entirety of a cohort recruited via open enrollment. Formal statistical power estimates were not performed, as the sampling strategy was based on maximal open enrollment capacity available at vaccination sites.
Data exclusions	No data were excluded from analyses.
Replication	No separate cohorts of comparable size are currently available for replication, to our knowledge.
Randomization	Randomization was not relevant to this experiment, as this was an observational study.
Blinding	Blinding was not relevant because of the observational study design (i.e. examining the differences in antibody levels between individuals previously identified as with versus without prior COVID-19).

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

### Methods

n/a	Involved in the study	n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies	<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines	<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology	<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern		

## Antibodies

Antibodies used	<p>Abbott Architect immunoassays (SARS-CoV-2 IgG and SARS-CoV-2 IgG II) from Abbott Labs were used to quantify circulating levels of SARS-CoV-2 anti-nucleocapsid (N) and anti-spike (S) antibodies.</p> <p>Abbott SARS-CoV-2 IgG II assay uses the following for IgG(S-RBD):            Paramagnetic Microparticles: Purified SARS-CoV-2 recombinant S-RBD antigen coated microparticles in TRIS buffer with surfactant.            Conjugate Antibody: Anti-human IgG (mouse, monoclonal) acridinium-labeled conjugate in MES buffer with surfactants and protein (bovine) stabilizer.</p> <p>The Abbott SARS-CoV-2 IgG assay uses the following for IgG(N):            Paramagnetic Microparticles: Purified SARS-CoV-2 recombinant N antigen coated microparticles in TRIS buffer with surfactant.            Conjugate Antibody: Anti-human IgG (mouse, monoclonal) acridinium-labeled conjugate in MES buffer with surfactant and protein (bovine) stabilizer.</p> <p>The ACE2 binding inhibition assay involves S-RBD coated magnetic microparticles (as for the IgG II quant assay) and a recombinant acridinium-labeled ACE2, and the signal decreases as ACE2 binding to S-RBD coated microparticles is reduced due to the presence of sample-specific neutralizing antibodies.</p>
Validation	Abbott SARS-CoV-2 immunoassays with validation reported in J Clin Microbiol. 2020;58(8):e00941-20.

## Human research participants

Policy information about [studies involving human research participants](#)

### Population characteristics

A diverse and unselected population of adults employed in a multi-site healthcare delivery system located in Los Angeles County, including individuals with direct patient contact and others with non-patient-oriented work functions. Our study sample is representative of the institution's diverse catchment area of 1.8 million, approximately half of whom identify as a racial or ethnic minority. Full cohort characteristics are outlined in Table 1 of the manuscript.

### Recruitment

Recruitment via newsletters and fliers, open to any Cedars-Sinai employees approved and scheduled for vaccine. Enrollment was not otherwise restricted based on any pre-specified criteria. We anticipate that our study results regarding the antibody response to vaccination is not unique to the characteristics of the healthcare workers who enrolled in this study and that, in turn, any unintended sampling biases would not materially impact the generalizability of results.

### Ethics oversight

Cedars-Sinai Institutional Review Board

Note that full information on the approval of the study protocol must also be provided in the manuscript.